



✂

... [illegible text]

... [illegible text]

... [illegible text]

... [illegible text]

... [illegible text]

... [illegible text]

... [illegible text]

... [illegible text]

... [illegible text]

... [illegible text]

1. Behrens A, Doyle JJ, Stern L (2006) Dysfunctional tear syndrome: A Delphi approach to treatment recommendations. *Cornea* 25: 900–907.
2. Nakamura H, Kawakami A, Eguchi K (2006) Mechanisms of autoantibody production and the relationship between autoantibodies and the clinical manifestations in Sjogren's syndrome. *Transl Res* 148: 281–288.
3. Vitali C, Bombardieri S, Jonsson R (2002) Östeoarthritis, Rheumatoid Arthritis, Sjögren's Syndrome: a revised version of the European criteria by the American-European Consensus Group. *Ann Rheum Dis* 61:554-558.
4. Smith JA, Albenz J, Begley C (2007) The epidemiology of dry eye disease: report of the epidemiology subcommittee of the international Dry Eye Workshop (2007). *Ocul Surf* 5: 93–107.
5. Miljanovic B, Dana R, Sullivan DA, Schaumberg DA (2007) Impact of dry eye syndrome on vision-related quality of life. *Am J Ophthalmol* 143: 409–415.
6. Schaumberg DA, Sullivan DA, Buring JE, Dana MR (2003) Prevalence of dry eye syndrome among US women. *Am J Ophthalmol* 136: 318–326.
7. Schaumberg DA, Sullivan DA, Dana MR (2002) Epidemiology of dry eye syndrome. *Adv Exp Med Biol* 506: 989–998.
8. Moss SE, Klein RK, Klein BEK (2000) Prevalence of and risk factors for dry eye syndrome. *Arch Ophthalmol* 118: 1264–1268.
9. Gayton JL (2009) Etiology, prevalence, and treatment of dry eye disease. *Clin Ophthalmol* 3: 405–412.
10. Clegg J, Guest J, Lehman A, Smith A (2006) The annual cost of dry eye syndrome in France, Germany, Italy, Spain, Sweden and the United Kingdom among patients managed by ophthalmologists. *Ophthalmic Epidemiol* 13: 263–274.